BridgeMD
New treatment option for Alzheimer's Dementia
Official title Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
ClinicalTrials.gov ID: NCT06534723
What this study is testing
What is Wujia Yizhi granules?
Wujia Yizhi granules is an investigational medicine, being studied as a potential treatment for alzheimer's dementia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 80
You may be able to join if
- Male or female, age range : 50 - 80 years old.
- Informed consent signed and dated by patient or legal representative.
- The participants are mild-to-moderate AD patients who meet the diagnostic criteria for AD proposed by the National Institute on Aging and the...
- MMSE score 11 to 26;CDR-GS score 1 to 2 。
You likely can't join if
- Participants with non AD induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed...
- Participants have a history of epileptic seizures.
- Participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium.
- HAMD-17 score ≥ 17 points.
- HAMA score ≥ 14 points.
- Participants were taking antidepressants, anxieties, and antipsychotic drugs during screening.
See the full eligibility criteria
- Male or female, age range : 50 - 80 years old.
- Informed consent signed and dated by patient or legal representative.
- The participants are mild-to-moderate AD patients who meet the diagnostic criteria for AD proposed by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2018 and have a disease course of more...
- MMSE score 11 to 26;CDR-GS score 1 to 2 。
- Participants with non AD induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed dementia (AD VaD), vascular dementia (VD), Parkinson's disease dementia...
- Participants have a history of epileptic seizures.
- Participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium.
- HAMD-17 score ≥ 17 points.
- HAMA score ≥ 14 points.
- Participants were taking antidepressants, anxieties, and antipsychotic drugs during screening.
- HIS score ≥ 4 points..
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.